GO
Loading...

Sanofi SA

More

  • The drug, developed by Vivus Inc, is marketed in the United States and Canada by Auxilium Pharmaceuticals Inc. Vivus' stock was up about 13 percent at $4.40 in afternoon trading.

  • The drug was developed by Auxilium Pharmaceuticals Inc and Vivus Inc.. Vivus owns the worldwide development and commercial rights to Stendra for use in sexual dysfunction, with the exception of certain Asian countries in the Pacific Rim.

  • The drug, developed by Vivus Inc, is marketed in the United States and Canada by Auxilium Pharmaceuticals Inc. Vivus' stock was up about 13 percent at $4.40 in afternoon trading.

  • Sept 18- An erectile dysfunction drug that reduces by half the time patients need to take the pill before sexual activity has been approved by the U.S. Food and Drug Administration.

  • Sept 15- Epirus Biopharmaceuticals Inc said India's drug regulator has approved its copy of a top-selling arthritis treatment, paving the way for its launch in the country early next year.

  • Sept 11- Ebola is just one of many neglected tropical diseases that badly need attention. The World Health Organization in 2012 designated 17 diseases as priorities for eradication or control:. There is no approved drug but the first vaccine from Sanofi could reach the market late next year.

  • The worst-ever Ebola outbreak, which has already killed at least 2,296 people in West Africa, has triggered a scramble to develop the first drug or vaccine for a deadly disease that was discovered nearly 40 years ago in the forests of central Africa.

  • Long-awaited diet pill gets U.S. approval Wednesday, 10 Sep 2014 | 9:00 PM ET

    Sept 10- A new diet pill Contrave got approval to be sold in the United States on Wednesday, only the third obesity treatment in more than a decade to win approval from the Food and Drug Administration.

  • Lilly receives European marketing OK for insulin Wednesday, 10 Sep 2014 | 10:13 AM ET

    INDIANAPOLIS— European regulators have approved a long-lasting insulin from Eli Lilly and Co. and German drugmaker Boehringer Ingelheim that is the subject of patent infringement litigation with French rival Sanofi. That is subject to a stay of more than two years due to the Sanofi litigation.

  • Sept 10- Eli Lilly and Co and Boehringer Ingelheim said on Wednesday that the European Commission approved their copycat version of Sanofi SA's blockbuster insulin, Lantus. The therapy received a positive recommendation from the European Medicine Agency in June.

  • Sept 5- Keryx Biopharmaceuticals Inc won U.S. approval for its drug to lower phosphate levels in patients with chronic kidney disease, but the approval included an unexpected safety warning on the label. However, the FDA- mandated label does not include the benefits of the drug in treating anemia.

  • Keryx Biopharma gets U.S. approval for kidney drug Friday, 5 Sep 2014 | 11:28 AM ET

    Sept 5- Keryx Biopharmaceuticals Inc won the U.S. Food and Drug Administration approval for its drug to lower phosphate levels in patients with chronic kidney disease who are already on dialysis. It affects more than 20 million adults in the United States, according to the U.S. Centers for Disease Control and Prevention.

  • *10 cents move in euro: 1 bln euro swing in Airbus's op profits. *Airbus, Sanofi, Luxottica seen among big winners.

  • PARIS, Sept 3- French drugmaker Sanofi, developing the first vaccine against dengue fever, said its product reduced disease cases by 60.8 percent in a large final clinical trial. Sanofi has invested more than 1.3 billion euros in the project, undertaking two decades of research on the world's fastest-growing tropical disease.

  • *Novartis's LCZ696 and PCSK9 drugs could treat millions. Hopes have spiked for a heart failure drug from Novartis and an innovative class of injectable anti-cholesterol agents known as PCSK9 inhibitors after the release of data at the ESC's annual meeting indicated that they can save more lives than standard therapies.

  • *Sanofi, Regeneron vying with drugs from Amgen and Pfizer. BARCELONA, Aug 31- An experimental cholesterol-lowering drug from Sanofi and Regeneron Pharmaceuticals roughly halved the number of heart attacks and strokes in a clinical trial, researchers reported on Sunday.

  • WASHINGTON, Aug 27- International Business Machines Corp on Wednesday launched a computer system that can quickly identify patterns in massive amounts of data, an ability that IBM said should hasten breakthroughs in science and medical research. IBM will make the service available through the cloud.

  • *Drug has orphan drug status in US, EU and Japan. Aug 20- Amicus Therapeutics Inc moved a step closer to bringing its first drug to the market after trial results paved the way for its lead drug to become the first oral treatment for patients with a disorder that causes an abnormal build-up of fat.

  • Aug 20- Amicus Therapeutics Inc said its experimental drug was as effective as enzyme replacement therapies after 18 months in patients with Fabry disease, an inherited disorder that leads to the abnormal build-up of fat. The company's stock rose 38 percent in premarket trading on Wednesday after the results of the second late-stage trial were released.

  • NORWICH, England, Aug 17- Pampering leafcutter ants with fragrant rose petals and fresh oranges may seem an unlikely way to rescue modern medicine, but scientists at a lab in eastern England think it's well worth trying.